The Goldman Sachs Group Has Lowered Expectations for Charles River Laboratories International (NYSE:CRL) Stock Price

Charles River Laboratories International (NYSE:CRL) had its price target decreased by The Goldman Sachs Group from $220.00 to $190.00 in a research report released on Thursday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the medical research company’s stock.

Several other equities analysts also recently commented on CRL. Evercore ISI upped their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday. Citigroup downgraded Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. TD Cowen upped their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Finally, Bank of America dropped their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $204.38.

Charles River Laboratories International Trading Down 0.9 %

Shares of Charles River Laboratories International stock opened at $166.75 on Thursday. Charles River Laboratories International has a 1 year low of $160.85 and a 1 year high of $275.00. The company has a market capitalization of $8.53 billion, a price-to-earnings ratio of 20.87, a P/E/G ratio of 5.97 and a beta of 1.38. The business has a fifty day simple moving average of $187.21 and a two-hundred day simple moving average of $197.51. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.72 EPS. Research analysts forecast that Charles River Laboratories International will post 10.18 EPS for the current year.

Insiders Place Their Bets

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Large investors have recently bought and sold shares of the business. Versant Capital Management Inc raised its stake in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Wolff Wiese Magana LLC acquired a new stake in Charles River Laboratories International in the third quarter valued at approximately $32,000. Pinnacle Bancorp Inc. grew its stake in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares during the last quarter. Assetmark Inc. increased its holdings in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares in the last quarter. Finally, ORG Wealth Partners LLC bought a new position in shares of Charles River Laboratories International in the 4th quarter valued at $56,000. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).